Figure 1: Liver tumors in c-Jun~Fra-2hepmice

A. Liver morphology and histology in a c-Jun~Fra-2hep and representative control mouse. Bar = 1 cm (top) and 100µm (H&E, bottom), tumors (T) are indicated by arrows and dotted line. B. Serum protein induced by vitamin K absence or antagonist-II (PIVKA), also known as des-gamma-carboxy-prothrombin (DCP). C. Serum alpha-fetoprotein (AFP) in c-Jun~Fra-2hep mice and littermate controls over time. D. AFP, Mcm2 and Sox9 immunohistochemistry (IHC) in c-Jun~Fra-2hep and control livers. Bar = 100µm, tumors (T) are indicated by a dotted line and arrows point to positive nuclei. E. qRT-PCR quantification of oncofetal, stemness and senescence-associated genes in c-Jun~Fra-2hep tumors and non-tumoral (NT) liver areas compared to controls. F. Gp73 and Bex immunoblot in livers extract from c-Jun~Fra-2hep mice (non-tumoral and tumors) and controls. G. Immunoblot for cell cycle-, replicative stress- and DNA damage-related proteins in liver extracts from c-Jun~Fra-2hep mice (non-tumoral and tumors) and controls. H. γH2AX IHC in liver sections of c-Jun~Fra-2hep mice and controls at 2 months and 9 of transgene expression (left) and quantification of hepatocyte (hep) γH2AX-positivity at 2 months (right). Bar = 100µm, tumors (T) are indicated by a dotted line and arrows point to positive nuclei. Unless otherwise indicated, all data are from mice with 9 months of transgene expression (off Dox at weaning). Gapdh and Vinculin are used to control loading. Bars = means ±SEM. * p<0.05, *** p<0.001 (t-test to controls).